KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer

PARP inhibitors (PARPi) are currently used as first-line therapy for advanced and recurrent ovarian cancer, but the clinical efficacy is limited by drug resistance. We aimed to investigate the role of KIAA1529 in PARPi resistance in ovarian cancer. The expression of KIAA1529 was determined in ovaria...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Yuan, Yu, Xuechen, Zhou, Bo, Zhang, Kai, Huang, Juyuan, Liao, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352548/
https://www.ncbi.nlm.nih.gov/pubmed/35917645
http://dx.doi.org/10.1016/j.tranon.2022.101497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352548/
https://www.ncbi.nlm.nih.gov/pubmed/35917645
http://dx.doi.org/10.1016/j.tranon.2022.101497

Ejemplares similares